gp160 vaccine
Vaccineexperimental
Clinical trial activity
19 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
19
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 2, 1999 (NCT00000957)
Timeline
1990s
- Jan 1, 1999
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gp160 vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00000630 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000631 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000667 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID), Protein Sciences Corp |
| NCT00000683 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000745 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID), Protein Sciences Corp |
| NCT00000746 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000757 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID), Protein Sciences Corp |
| NCT00000762 | Phase 1 | Nov 2, 1999 | Genentech, National Institute of Allergy and Infectious Diseases (NIAID), Protein Sciences Corp |
| NCT00000777 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000782 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000822 | Phase 1 | Nov 2, 1999 | Bristol-Myers Squibb, Immuno US, Inc., National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000956 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID), Protein Sciences Corp |
| NCT00000957 | Phase 1 | Nov 2, 1999 | Immuno US, Inc., National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000968 | Phase 1 | Nov 2, 1999 | Immuno US, Inc., National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000977 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID), Protein Sciences Corp |
| NCT00001037 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00001043 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00001056 | Phase 1 | Nov 2, 1999 | Immuno US, Inc., National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00002261 | Phase 1 | Nov 2, 1999 | Bristol-Myers Squibb |
Showing 19 of 19 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 18 | 18 | 1 | 1999 |
| Protein Sciences Corp | For profit | 6 | 0 | 1 | 1999 |
| Immuno US, Inc. | For profit | 4 | 0 | 1 | 1999 |
| Bristol-Myers Squibb | For profit | 2 | 1 | 1 | 1999 |
| Genentech | For profit | 1 | 0 | 1 | 1999 |
5 organizations
Page 1 / 1